Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Medical Equipment

CERS:US

5.4900 USD 0.1300 2.43%

As of 20:10:00 ET on 01/28/2015.

Snapshot for Cerus Corp (CERS)

Open: 5.3700 Day's Range: 5.3100 - 5.6200 Volume: 1,540,215
Previous Close: 5.3600 52wk Range: 3.4800 - 8.0000 1-Yr Rtn: -10.29%

Stock Chart for CERS

No chart data available.
  • CERS:US 5.4850
  • 1D
  • 1M
  • 1Y
5.3600
Interactive CERS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CERS

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.3811
Est. EPS (USD) (12/2014) -0.5320
Est. PEG Ratio -
Market Cap (M USD) 493.74
Shares Outstanding (M) 89.93
30 Day Average Volume 2,051,072
Price/Book (mrq) 9.0892
Price/Sale (ttm) 11.0875
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/25/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CERS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CERS

Cerus Corporation develops systems designed to enhance the safety of blood transfusions. The Company's systems inactivate pathogens in blood components and inactivate white blood cells, which are responsible for a variety of adverse transfusion reactions. Cerus' platform technologies prevent viral, bacterial, and cellular replication.

William Mariner Greenman "Obi"President/CEOChrystal N MenardChief Legal Officer
Caspar HogeboomPres:Cerus EuropeLaurence M CorashSenior VP/Chief Medical Ofcr/Co-Founder
More Company Profile & Key Executives for CERS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil